Raloxifene: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Raloxifene. Educational only — not medical advice.

Labeled uses

EVISTA® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. (1.1 ) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. (1.2 ) Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. (1.3 ) Important Limitations: EVISTA is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer. (1.3 )

Source: FDA labeling via NIH DailyMed (set fcaaa6dc…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.